medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Número 2

<< Anterior Siguiente >>

Rev Mex Neuroci 2008; 9 (2)


Alteraciones inmunológicas en la esclerosis múltiple

Uribe Jaimes PD, Núñez OL

Idioma: Español
Referencias bibliográficas: 29
Paginas: 150-153
Archivo PDF: 48.28 Kb.


RESUMEN

A la esclerosis múltiple se le conoce como una enfermedad desmielinizante del sistema nervioso central inflamatoria y degenerativa, la cual se presenta primordialmente en las mujeres entre los 20 y 40 años. En la etiología de esta enfermedad se han implicado factores genéticos, inmunológicos y ambientales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Minden SL, Marder WD, Harrold LN, et al. Multiple sclerosis. A statistical portrait. National Multiple Sclerosis Society Report. Cambridge MA. 1991.

  2. CoronaT. Multiple sclerosis in Mexico: hospital cases at the National Institute of Neurology and Neurosurgery, Mexico City. Neurologia 1996; 11(5): 170-3.

  3. Dyment DA. Genetics of multiple sclerosis. Hum Mol Genet 1997; 6: 1693-8.

  4. Siblye WA, Bamford CR, Clark C. Clinical viral infectons and multiple sclerosis. Lancet 1985; 1: 1313-15.

  5. Hemachudha T. MBP as an encephalitogen in encephalomuelitis and polyneuritis following rabies vaccination. N Eng J Med 1987; 316: 369.

  6. Zamvil SS, Steinman I. The T lymphocite in experimental allergic enchepalomyelitis. Ann Rev Immunol 1990; 49: 53-61.

  7. Antel JP, Nicholas MK, Bania MB, et al. Comparison of T8 cell mediated supresor and cytotoxic function in MS. J Neuroimmunol 1986; 12: 215-24.

  8. Gallo P, Piccino M, Pagni S, et al. Immune activation in MS: study of IL-2, sIL-2R and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989; 92: 9-15.

  9. Bansil S, Troiano R, Cook SD, et al. Serum soluble IL-2R levels in chronic progressive, stable and steroid treated MS. Acta Neurol Scand 1991; 84: 282-5.

  10. Sharief M, Hentges R. Association between tumor necrosis factor – alpha and disease progression in patients with MS. N Engl J Med 1991; 325: 467-72.

  11. Hartung HP, Michels M, Reiners K, et al. Soluble ICAM-1 serum levels in MS and viral encephalitis. Neurology 1993; 43: 2331-5.

  12. Beck J, Rondot P, Jullien P, et al. TGF like activity produced during regression of exacerbations in MS. Acta Neurol Scand 1991; 84: 452-5.

  13. Chou YK, Bourdette DN, Offner H, et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in MS. J Neuroimmunol 1992; 38: 105-14.

  14. Sun JB, Link H, Olsson T, et al. T and B cell responses to myelinoligodendrocyte protein in MS. J Immunol 1991; 146: 1490-5.

  15. Warren KG, Catz I, Johnson E, et al. Anti myelin basic protein and anti proteolipid protein specific forms of MS. Ann Neurol 1994; 35: 280-9.

  16. Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specif cytotoxic T cell lines from MS patients and healthy individuals. J Immunol 1990; 145: 540-8.

  17. Jaraquemada R, Martin R, Rosen R, et al. HLA-DR2 is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol 1990; 145: 2880-5.

  18. Wucherpfennig KW, Ota K, Endo N, et al. Shared human T cell receptor Vb usage to immunodominant regions of myelin basic protein, Science 1990; 248: 1016-19.

  19. Utz U, Biddison WE, McFarland HF, et al. Skewed T cell repertoire in genetically identical twins with MS. Nature 1993; 364: 243-7.

  20. Pelfrey CM, Trotter JL, Tranquill F, et al. Identification of a novel T cell epitope of human proteolypid protein (residues 40-60) recognized by proliferative and cytolytic CD4 T cells from MS patients. J Neuroimmunol 1993; 46: 33-42.

  21. Chofflon M, Weiner HL, Morimoto C, et al. Decrease of supressor inducer T cells in MS cerebrospinal fluid. Ann Neurol 1989; 25: 494-9.

  22. Svenningson A, Hansson GK, Anderson O, et al. Adhesion molecule expression in crebrospinal fluid T lymphocites: mechanisms in MS, aseptic meningitis and normal controls. Ann Neurol 1993; 34: 155-61.

  23. Sharief MK, Mentges R, Ciardi M, et al. In vivo relationship of IL-2 and soluble IL-2 receptor to blood brain barrier impairment in patients with active MS. J Neurol 1993; 240: 46-50.

  24. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor alpha to blood barin barrier damage in patients with actuve MS. J Neuroimmunol 1992; 38: 27-34.

  25. Traugott U, Reinherz EL, Raine CS. MS: distribution of T cells subsets within active chronic lesions. Science 1983; 219: 308-10.

  26. Sobler RA, Hatler DA, Castro E, et al. The 2H4 (CD45R) antigen is selectively decreased in MS lesions. J Immunol 1988; 140: 2210-14.

  27. Sobel RA, Mitchell ME, Fronderen G, et.al. Intercellular adhesion molecule 1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 136: 1309-16.

  28. Freedman MS, Tuijs TG, Selin LK, et.al. Peripheral blood gammadelta T cells lyse fredh human brain derived oligodendrocytes. Ann Neurol 1991; 30: 794-800.

  29. Bö L, Dawson TM, Wesseling S, et al. Induction of nytric oxide synthase in demyelinating region of MS brains. Ann Neurol 1994; 36: 778-86.




2020     |     www.medigraphic.com